Back
Krystal Biotech, Inc. (KRYS)
BiotechnologyKRYS · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$355.85
+4.18%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$6.84
ROE
19.9%
Gross margin
94.2%
Debt/Equity
0.71x
Revenue growth
31.9%
Krystal Biotech, Inc. — company intelligence
Earnings surprises
Q2 2026$1.79 vs $1.69 est+6.0%
Q1 2026$1.83 vs $1.45 est+26.3%
Q4 2025$1.70 vs $1.44 est+18.3%
Q3 2025$2.66 vs $1.11 est+140.2%
Analyst consensus · 18 analysts
16 Buy2 Hold0 Sell
Updated Aug 21, 2026
Insider activity · 90 days
0 buys30 sellsnet -75,000 shares
ROSSI DINO ASell 40 · Aug 14, 2026
ROSSI DINO ASell 341 · Aug 14, 2026
ROSSI DINO ASell 1,687 · Aug 14, 2026
Recent SEC filings
4 — Insider transaction reportAug 14, 2026
8-K — Material event reportAug 3, 2026
10-Q — Quarterly reportAug 3, 2026
Latest news
Krystal Biotech (NASDAQ:KRYS) Clears Minervini Trend Template and High Growth Momentum Screen — ChartMill · 3d ago
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says — Yahoo · 1w ago
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400 — Benzinga · 1w ago
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.